While cyclin D1 is overexpressed in cancer, wild type cyclin D1 is poorly oncogenic. Through work supported by this grant, we have pioneered the resolution to this paradox. Importantly, our work has revealed a paradigm wherein cyclin D1 accumulates in the nucleus during G1 phase; however, at the G1/S boundary, phosphorylation of a single threonyl residue, Thr-286, by GSK-3b triggers cyclin D1 nuclear export and its cytoplasmic ubiquitin-mediated proteolysis. A non-phosphorylatable mutant, D1T286A, is constitutively nuclear, refractory to poly- ubiquitination and has potent oncogenic properties. An instrumental finding during the previous four years was the demonstration that accumulation of active nuclear cyclin D1/CDK4 kinase during S-phase triggers DNA re-replication, induces genomic instability and inactivation of p53; all a consequence of its capacity to activate the arginine methyltransferase PRMT5. It is now evident that cyclin D1 is subject to frequent mutations that directly inhibit Thr-286 phosphorylation, thereby demonstrating that cyclin D1 as a driver oncogene. Examples include uterine cancer, esophageal, melanoma and multiple myeloma. Since current models depend on overexpression of mutant alleles from ectopic promoters, we have generated a new model that allows inducible expression of the mutant D1T286A from its endogenous promoter. We hypothesize that expression of cyclin D1T286A from its endogenous promoter will drive neoplastic growth and will permit the generation of mouse models of human cancer that mimic somatic mutation of cyclin D1. In addition, while much effort has been focused on cyclin D1 due to its frequent dysregulation in cancer, it is now evident that cyclin D3 is subject to an analogous mutation in Burkitt?s lymphoma where the conserved c-terminal phosphorylation site, Thr-283 in D3, is mutated to a non-phosphorylatable residue. Such mutations co-occur with myc- translocations at a frequency approaching 50%. This revelation highlights a gap in knowledge regarding how phosphorylation of D3 contributes to its regulation and cell homeostasis. We therefore hypothesize that Thr-283 phosphorylation directs cyclin D3 for export to the cytoplasm where it is ubiquitylated and degraded. These gaps in knowledge will be directly addressed through three cohesive aims:
Aim 1 will determine the neoplastic activity of cyclin D1T286A using an inducible knockin mouse model that permits expression from its endogenous promoter;
Aim 2 will determine the role of Fbxl8 in ubiquitylation of Thr-283 phosphorylated cyclin D3;
Aim 3 will determine the tumor suppressive function of Fbxl8 and whether non-phosphorylatable cyclin D3T283A exhibits enhanced ability to drive lymphoma.

Public Health Relevance

. Overexpression of D-type cyclins occurs frequently in human cancer and genomic sequencing has revealed that D-type cyclins is subject to mutations that impair ubiquitin-dependent degradation and nuclear export. However, the contribution of phosphorylation to degradation of cyclins D2 and D3 and whether phosphorylation prevents their oncogenicity is unknown. The experiments described in this proposal will generate relevant models cancer driven by cancer derived D-type cyclin mutants, evaluate the role of phosphorylation in their regulation and assess mechanisms of tumor initiation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA093237-19
Application #
9928365
Study Section
Molecular Oncogenesis Study Section (MONC)
Program Officer
Watson, Joanna M
Project Start
2001-07-01
Project End
2023-05-31
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
19
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
de Leeuw, Renée; McNair, Christopher; Schiewer, Matthew J et al. (2018) MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer. Clin Cancer Res 24:4201-4214
Qie, Shuo; Majumder, Mrinmoyee; Mackiewicz, Katarzyna et al. (2017) Fbxo4-mediated degradation of Fxr1 suppresses tumorigenesis in head and neck squamous cell carcinoma. Nat Commun 8:1534
Qie, Shuo; Diehl, J Alan (2016) Cyclin D1, cancer progression, and opportunities in cancer treatment. J Mol Med (Berl) 94:1313-1326
Cárdenas, César; Müller, Marioly; McNeal, Andrew et al. (2016) Selective Vulnerability of Cancer Cells by Inhibition of Ca(2+) Transfer from Endoplasmic Reticulum to Mitochondria. Cell Rep 15:219-220
Diehl, J Alan (2016) Cyclin D3: To translate or not to translate. Cell Cycle 15:3018-3019
Lian, Zhaorui; Lee, Eric K; Bass, Adam J et al. (2015) FBXO4 loss facilitates carcinogen induced papilloma development in mice. Cancer Biol Ther 16:750-5
Yoshida, Akihiro; Diehl, J Alan (2015) CDK4/6 inhibitor: from quiescence to senescence. Oncoscience 2:896-7
Li, Yan; Diehl, J Alan (2015) PRMT5-dependent p53 escape in tumorigenesis. Oncoscience 2:700-2
Augello, Michael A; Berman-Booty, Lisa D; Carr 3rd, Richard et al. (2015) Consequence of the tumor-associated conversion to cyclin D1b. EMBO Mol Med 7:628-47
Li, Yan; Chitnis, Nilesh; Nakagawa, Hiroshi et al. (2015) PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers. Cancer Discov 5:288-303

Showing the most recent 10 out of 35 publications